Clinical Trials · NCT04740645
NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 1,099,551
- Start date
- Jul 2021
- Locations
- 3 sites, 3 countries
- Primary endpoint
- Incidence rate of symptomatic hyponatraemia